Search Results

Zonisamide 100 mg  | 99.90%

TargetMol

Zonisamide, a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or […]

More Information Supplier Page

Zonisamide 200 mg  | 99.90%

TargetMol

Zonisamide, a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or […]

More Information Supplier Page

Clofarabine 10 mg  | 100.00%

TargetMol

Clofarabinem, a second generation purine nucleoside analog with antineoplastic activity, inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.

More Information Supplier Page

Linagliptin 100 mg  | 99.15%

TargetMol

Linagliptin is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity.

More Information Supplier Page

Ranolazine dihydrochloride 100 mg  | 100.00%

TargetMol

Ranolazine(RS-43285), an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate.

More Information Supplier Page

Ranolazine dihydrochloride 200 mg  | 100.00%

TargetMol

Ranolazine(RS-43285), an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate.

More Information Supplier Page